Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Amr I. Al Abbas"'
Autor:
Mazen S. Zenati, Amer H. Zureikat, Melissa E. Hogg, Amr I. Al Abbas, Herbert J. Zeh, Jae Pil Jung, Caroline J. Reiser, Ahmad Hamad
Publikováno v:
Ann Surg Oncol
INTRODUCTION: Optimal cut-offs for CA19-9 response after neoadjuvant therapy (NT) for pancreatic adenocarcinoma (PDAC) are not well characterized. This study aims to analyze the relationship of serum CA19-9 with other markers of response and identify
Autor:
Amr I, Al Abbas, Melissa E, Hogg
Publikováno v:
Annals of surgical oncology. 27(6)
Autor:
Alessandro, Paniccia, Ana L, Gleisner, Mazen S, Zenati, Amr I, Al Abbas, Jae Pil, Jung, Nathan, Bahary, Kenneth K W, Lee, David, Bartlett, Melissa E, Hogg, Herbert J, Zeh, Amer H, Zureikat
Publikováno v:
Annals of surgical oncology. 27(8)
Neoadjuvant therapy (NT) is a growing strategy in localized head pancreatic adenocarcinoma (PDC). However, a significant portion of NT patients do not reach resection due to disease progression or performance status decline. We sought to identify pre
Autor:
Pranav Murthy, Amr I. Al Abbas, Mazen S. Zenati, Nathan Bahary, Michael T. Lotze, Amer H. Zureikat, Brian A. Boone, Caroline J. Rieser, Herbert J. Zeh
Publikováno v:
Ann Surg Oncol
BACKGROUND. The systemic immune-inflammation index (SII), calculated using absolute platelet, neutrophil, and lymphocyte counts, has recently emerged as a predictor of survival for patients with pancreatic ductal adenocarcinoma (PDAC) when assessed a
Autor:
Ahmad Hamad, Melissa E. Hogg, Caroline J. Rieser, Amr I. Al Abbas, Amer H. Zureikat, Nathan Bahary, Mazen S. Zenati, Herbert J. Zeh
Publikováno v:
Annals of surgical oncology. 25(12)
Serum carbohydrate antigen 19-9 (CA19-9) correlates with response to therapy and overall survival (OS) for patients with pancreatic ductal adenocarcinoma (PDAC). This study aimed to define the chronologic relationship between CA19-9 elevation and rad